Table of Contents
I. PAR-15-120: Identification of Genetic and Genomic Variants by Next-Gen Sequencing in Non-human Animal Models (U01)
II. PAR-16-357: The Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1).
III. PAR-16-291: Integrative Research on Polysubstance Abuse and Addiction (R21/R33)
IV. PAR-16-383: Chemistry Science Track Award for Rapid Transition (C/START)(R03)
V. PAR-16-384: Chemical Discovery (CHEM) Award (R21/R33)
VI. RFA-DA-17-013: The Mechanisms of Immune Activation and Inflammation: HIV Infection, ART, and Drugs of Abuse (R01)
------------------
I. PAR-15-120: Identification of Genetic and Genomic Variants by Next-Gen Sequencing in Non-human Animal Models (U01) - See more at: http://grants.nih.gov/grants/guide/pa-files/PAR-15-120.html#sthash.BmUCzrQH.dpuf
Next Application Deadline: October 20, 2016
The goals of this initiative are to identify gene variants of traits associated with addiction and substance abuse in selectively bred, and outbred non-human animal models using methodologies of Next Gen-Sequencing, mapping, and genotyping.
-----------------
II. PAR-16-357: The Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1). http://grants.nih.gov/grants/guide/pa-files/PAR-16-357.html.
Letter of Intent: September 19, 2016
Application Deadline: October 19, 2016 by 5:00PM local time of application organization.
This funding opportunity is for early stage investigators who are within 10 years of completing their terminal degree, hold an independent career position by September 1, 2016, and has not received a significant independent research award such as an R01. I encourage early stage investigators outside of the field of drug abuse and addiction to apply.
The Genetics or Epigenetics of Substance Use Disorders Avenir Award program supports early stage investigators proposing highly innovative studies that open new areas of research for the genetics or epigenetics of addiction. These may be novel methods or approaches that can potentially be applied to the analysis of the genetics or epigenetics of addiction. Investigators outside the field of addiction interested in applying their novel approaches to the genetics or epigenetics of addiction are encouraged to apply. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field of genetics or epigenetics of substance use disorders.
If you are interested please read the entire announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-16-357.html.
----------------------
III. PAR-16-291: Integrative Research on Polysubstance Abuse and Addiction (R21/R33) http://grants.nih.gov/grants/guide/pa-files/PAR-16-291.html
Next Application Deadline: October 16, 2016
NIDA has recently published a new FOA entitled Integrative Research on Polysubstance Abuse and Addiction (http://grants.nih.gov/grants/guide/pa-files/PAR-16-291.html). The intent of this FOA is two-fold: (1) characterize how the neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies. These dual objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, where polysubstance research can occur in any of these translational stages during the R21 phase and these findings will be rapidly back- or forward-integrated into another stage during the R33 phase, allowing for bi-directional research exchange. If you have further inquiries regarding this new announcement, please contact Dr. Shelley Su at shelley.su@nih.gov.
-----------------------
IV. PAR-16-383: Chemistry Science Track Award for Rapid Transition (C/START)(R03) http://grants.nih.gov/grants/guide/pa-files/PAR-16-383.html
Next Application Deadline: October 16, 2016
The National Institute on Drug Abuse (NIDA) seeks to facilitate the entry of new/early stage investigators (ESIs) into substance use disorder (SUD) research. ESIs are invited to submit applications for small scale, innovative chemical/pharmacological pilot research projects. Importantly, the C/START award is intended to enable an ESI the opportunity to gather preliminary data in support of subsequent research grants (e.g., R21/R33 [CHEM], R21 or R01) or drug development funding opportunities that, in the long term, help to launch the ESI’s scientific career.
------------------------
V. PAR-16-384: Chemical Discovery (CHEM) Award (R21/R33) http://grants.nih.gov/grants/guide/pa-files/PAR-16-384.html
Next Application Deadline: October 16, 2016
The purpose of this FOA is to support the development of chemical probes that aid basic research investigations on substance use disorders (SUDs) or identify new lead chemical scaffolds with potential for structure activity relationship (SAR) studies on SUDs. In the long term, it is hoped that these lead chemical scaffolds will provide a greater number of pharmacological tools for basic research and possible drug candidates for medications development.
------------------------------
VI. RFA-DA-17-013: The Mechanisms of Immune Activation and Inflammation: HIV Infection, ART, and Drugs of Abuse (R01) http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-17-013.html
Application Due Date: November 18, 2016
The purpose of this FOA is to promote research to investigate the underlying molecular mechanisms of HIV infection-induced immune activation and inflammation in the presence of antiretroviral therapy (ART) agents and drugs of abuse. The ultimate goal is to obtain information for developing therapeutic interventions for attenuating chronic inflammation-associated comorbidities as well as for restoring or improving ART efficacy in HIV-infected drug-abusing populations.
The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov 301-435-1309
No comments:
Post a Comment